Agenus has been granted a patent for T cell receptors (TCRs) that bind to MLL phosphopeptides, which can be used in the treatment of subjects. The patent also covers cells, pharmaceutical compositions, nucleic acids, expression vectors, and host cells related to these TCRs. The isolated TCRs have specific amino acid sequences as described in the claim. GlobalData’s report on Agenus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agenus, Personalized cancer vaccines was a key innovation area identified from patents. Agenus's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for t cell receptor (tcr) sequences
A recently granted patent (Publication Number: US11718658B2) discloses an isolated T cell receptor (TCR) with specific amino acid sequences. The TCR includes various complementarity determining regions (CDRs) that play a crucial role in antigen recognition. The patent claims cover different combinations of CDR sequences for both the alpha (a) and beta (ß) chains of the TCR.
Claim 1 of the patent describes the TCR with specific CDR sequences for both the alpha and beta chains. The patent also covers variations of these sequences in subsequent claims. Claim 2 specifies that the TCR is of human origin, indicating its potential relevance for human therapeutic applications.
The patent also includes claims related to engineered cells that express the TCR on their surface. Claim 3 describes an engineered cell presenting the TCR, while claim 4 specifies that the cell can be a T cell, CD8+ T cell, CD4+ T cell, natural killer T (NKT) cell, or natural killer (NK) cell. Claim 5 further includes invariant natural killer T (iNKT) cells and mucosal-associated invariant T (MAiT) cells as potential cell types.
Additionally, the patent covers a pharmaceutical composition comprising the TCR and a pharmaceutically acceptable carrier (claim 6). This suggests the potential use of the TCR in therapeutic applications.
Claims 7 and 8 describe alternative amino acid sequences for the alpha and beta chains of the TCR, expanding the scope of the patent. These claims provide additional options for the TCR design and potential applications.
The patent also includes claims related to specific CDR sequences (claims 9-12) and alternative alpha and beta chain sequences (claims 13-15). These claims further demonstrate the versatility and potential variations of the TCR design.
Finally, claims 16-21 reiterate the potential applications of the TCR in engineered cells, specifying different cell types and pharmaceutical compositions.
Overall, this granted patent discloses an isolated TCR with specific amino acid sequences and covers various combinations and variations of these sequences. The patent's claims highlight the potential applications of the TCR in engineered cells and pharmaceutical compositions, particularly in the context of human therapeutics.
To know more about GlobalData’s detailed insights on Agenus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
